Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06279299 |
| Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision |
| recruiting |
| N/A |
| 30 |
| National Cancer Center, ChinaOTHER |
| 1 |
| Feb 28, 2024 |
| clinicaltrials |
| NCT06277180 | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06247605 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | recruiting | Phase 3 | 243 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06155318 | 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours | recruiting | — | 300 | IRCCS San RaffaeleOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT04790253 | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)(PRIMALung) | recruiting | N/A | 600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Nov 3, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06070740 | First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | recruiting | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06015802 | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05797493 | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer(PICASSO) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05673031 | 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors | recruiting | — | 500 | Alberta Health servicesOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04949282 | Spanish Series of Patients Treated With the Radionuclide Lutetium177(SEPTRALU) | recruiting | — | 5,000 | Sociedad Española de Medicina Nuclear e Imagen MolecularOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04829708 | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy | recruiting | Phase 3 | 534 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03344016 | Multicenter Pheochromocytoma and Paraganglioma Evaluation(MUPPET) | recruiting | N/A | 1,148 | Felix BeuschleinOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03014687 | Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions(POET) | recruiting | Phase 4 | 116 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Aug 15, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Mar 15, 2024source: clinicaltrials